RVL Pharmaceuticals plc. announced its preliminary second quarter FY22 sales from Upneeq of $8.4 million. The figure represents a +42% growth sequentially.
Upneeq is an approved ophthalmic solution for droopy eyelids.
The company also mentioned that it had received orders from approximately 2,200 cumulative unique medical aesthetics practices from February through June of 2022.
CEO Brian Markison said, “ As planned and previously announced, we expect to significantly expand our medical aesthetics salesforce by mid to late July and believe that we are well-positioned to build on our momentum and achieve our fourth quarter 2022 net sales projection."
RVL reaffirmed its outlook on Q4 Upneeq sales in the range of $20 million to $25 million.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where RVLP advanced for three days, in of 225 cases, the price rose further within the following month. The odds of a continued upward trend are .
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where RVLP's RSI Indicator exited the oversold zone, of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 56 cases where RVLP's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for RVLP just turned positive on May 10, 2023. Looking at past instances where RVLP's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .
The Momentum Indicator moved below the 0 level on May 25, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on RVLP as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Aroon Indicator for RVLP entered a downward trend on May 18, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.186) is normal, around the industry mean (24.947). P/E Ratio (0.000) is within average values for comparable stocks, (122.964). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.308). Dividend Yield (0.000) settles around the average of (0.031) among similar stocks. P/S Ratio (2.223) is also within normal values, averaging (307.036).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. RVLP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RVLP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of generic pharmaceutical products
Industry Biotechnology
A.I.dvisor tells us that RVLP and VIRX have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RVLP and VIRX's prices will move in lockstep.
Ticker / NAME | Correlation To RVLP | 1D Price Change % | ||
---|---|---|---|---|
RVLP | 100% | +4.76% | ||
VIRX - RVLP | 29% Poorly correlated | +6.02% | ||
PTCT - RVLP | 27% Poorly correlated | +3.65% | ||
ALZN - RVLP | 25% Poorly correlated | +6.44% | ||
RVNC - RVLP | 25% Poorly correlated | -0.49% | ||
APLS - RVLP | 25% Poorly correlated | +1.70% | ||
More |